Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Transitional Cell × valrubicin × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2 Carcinoma in Situ 2 Virus Diseases 1 Neoplasms 1 Carcinoma, Transitional Cell 1 Adenoviridae Infections 1

Interventions

Gemcitabine 4 Cisplatin 2 vinflunine 1 valrubicin 1 pembrolizumab 1 enfortumab vedotin 1 cabazitaxel 1 XRP6258 1 Rogaratinib 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Drug Therapy 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡